Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4858774
Max Phase: Preclinical
Molecular Formula: C53H69F15N14O17
Molecular Weight: 889.08
Molecule Type: Unknown
Associated Items:
ID: ALA4858774
Max Phase: Preclinical
Molecular Formula: C53H69F15N14O17
Molecular Weight: 889.08
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)N[C@@H](CCCN)C(=O)NC(=O)[C@H](C)NC(=O)[C@H](CCNC(=N)N)NCCN1CCN(CC(=O)NC2CCN(CC(=O)N3c4ccccc4NC(=O)c4ccccc43)CC2)CC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C43H64N14O7.5C2HF3O2/c1-28(39(61)53-42(64)34(10-7-16-44)50-29(2)58)49-41(63)33(13-17-48-43(45)46)47-18-21-54-22-24-56(25-23-54)26-37(59)51-30-14-19-55(20-15-30)27-38(60)57-35-11-5-3-8-31(35)40(62)52-32-9-4-6-12-36(32)57;5*3-2(4,5)1(6)7/h3-6,8-9,11-12,28,30,33-34,47H,7,10,13-27,44H2,1-2H3,(H,49,63)(H,50,58)(H,51,59)(H,52,62)(H4,45,46,48)(H,53,61,64);5*(H,6,7)/t28-,33-,34-;;;;;/m0...../s1
Standard InChI Key: JGRILCAPJREQOW-ROVXKKNJSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 889.08 | Molecular Weight (Monoisotopic): 888.5082 | AlogP: -1.66 | #Rotatable Bonds: 20 |
Polar Surface Area: 292.55 | Molecular Species: BASE | HBA: 13 | HBD: 10 |
#RO5 Violations: 3 | HBA (Lipinski): 21 | HBD (Lipinski): 12 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.38 | CX Basic pKa: 15.28 | CX LogP: -4.58 | CX LogD: -8.49 |
Aromatic Rings: 2 | Heavy Atoms: 64 | QED Weighted: 0.05 | Np Likeness Score: -0.53 |
1. Weinhart CG, Wifling D, Schmidt MF, Neu E, Höring C, Clark T, Gmeiner P, Keller M.. (2021) Dibenzodiazepinone-type muscarinic receptor antagonists conjugated to basic peptides: Impact of the linker moiety and unnatural amino acids on M2R selectivity., 213 [PMID:33571911] [10.1016/j.ejmech.2021.113159] |
Source(1):